NEW YORK (GenomeWeb News) – WaferGen Bio-systems reported in its 10-K filing with the US Securities and Exchange Commission this week that its fourth-quarter 2008 revenues fell 60 percent, following three successive quarters of significant increases in revenue.

The Fremont, Calif.-based firm brought in revenues of $65,424 for the three-month period ended Dec. 31, 2008, compared to $161,513 for the comparable period the year before. It did not provide a reason in the filing for the sharp year-over-year decline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.